In primary HIV infection Immediate (but transient) cART suggests an immunological benefit over deferred cART; clinical benefits have not been reported. There are no studies on continuous cART in this setting. Here we studied the long-term effects of immediate (continuous) cART on immune recovery, mortality and clinical events in comparison with deferred cART in persons with PHI.
From 1996 all individuals in the OLVG with a documented hiv seroconversion within 1 year (=PHI) were identified and divided in two groups: immediate cART (initiated < 3 mo. after Dx) versus deferred cART (initiated > 3 mo. after Dx). Differences in outcomes between groups were analysed for the following outcomes: immune recovery at 2, 5, and 10 years after diagnosis (CD4 counts and CD4-CD8 ratios), mortality, AIDS-related events, cardiovascular events and malignancies. Statistical analysis: Fishers Exact, Mann Whitney U test; Kaplan-Meier curves and the log rank test to compare survival curves between groups.
A total of 370 patients with PHI were included: 91 initiated cART within 3 months (median 1 mo., IQR 0-2 mo.)(9 interrupted cART temporarily) and 279 initiated cART after 3 months (median 25 mo., IQR 14-44 mo.). Median follow-up was longer for the deferred group (6 yrs (IQR 4-10)) compared with the immediate group (3 yrs (IQR 2-7)) (p<0,001). No significant differences between groups were found in CD4 and CD4/CD8 ratio at 5 years (median 560.0 cells/mm3 vs. 590.0 cells/mm3, p=0.572; median 0.71 vs. 0.62, p=0.084) and 10 years after diagnosis (median 550.0 cells/mm3 vs. 580.0 cells/mm3, p=0.264; median 0.74 vs. 0.66, p=0.329). Outcome rates (and KM curves) did not differ significantly between groups for mortality (2.2% vs. 5.4%, p=0,261), AIDS-related events (5.5% vs. 9.7%, p=0.218) and cardiovascular events (2.2% vs. 4.3%, p=0.532). A total of 25 malignancies (12 AIDS related; 13 non AIDS related) occurred only in the deferred group and differed therefore significantly with the immediate group (0% v. 9,0%, p=0.003)(Figure). Results remained similar when the 9 interrupters in the immediate group were excluded from the analyses.
Immediate cART provided no benefits over deferred cART in primary HIV infection for immune recovery, mortality, AIDS-related events, and cardiovascular events. However, immediate cART significantly reduced the risk of AIDS-defining and non-AIDS-defining malignancies in this setting.